Moderate glucose supply reduces hemolysis during systemic inflammation

Area of Science:

• Physiology
• Biochemistry
• Pathology

Background:

• Systemic inflammation disrupts energy metabolism, critically affecting erythrocytes which rely solely on glucose.
• Erythrocyte damage (hemolysis) and glucose metabolism disorders increase mortality risk.
• Understanding glucose's role in inflammation-induced hemolysis is crucial for patient outcomes.

Purpose of the Study:

• To investigate the impact of intravenous glucose administration on hemolysis during systemic inflammation.
• To evaluate glucose's effect on hemodynamic and metabolic changes induced by lipopolysaccharide (LPS).

Main Methods:

• Male Wistar rats underwent continuous lipopolysaccharide (LPS) infusion to induce systemic inflammation.
• Rats received either moderate or excessive intravenous glucose supply during LPS infusion.
• Vital signs, blood parameters (glucose, lactate, cell-free hemoglobin, lactate dehydrogenase), and clot formation were monitored.

Main Results:

• LPS infusion caused a post-aggression syndrome, including hemodynamic changes, metabolic disturbances, tissue injury, coagulation issues, and massive hemolysis.
• Intravenous glucose, particularly excessive supply, partially mitigated LPS-induced hypertension.
• Glucose administration significantly reduced LPS-induced hemolysis by up to 35% without improving coagulation.

Conclusions:

• Intravenous glucose infusion effectively diminishes hemolysis during systemic inflammation.
• Reducing hemolysis, a predictor of survival, via glucose administration offers a strategy to minimize mortality in sepsis.
• Further research into glucose's protective effects on erythrocytes in inflammatory conditions is warranted.